IMHO, March 2012 was a turning point for IPHI. The USPTO upheld all patent infringement claims by Netlist, inc., against IPHI. Inphi's business model was built around the promise of their LRDMM technology. Now, it seems that they just went to a JEDEC conference and copied it from Netlist. When final action at the USPTO comes about, what do you think IPHI stock will do? Remember METARAM?(some of the SAME folks, too.)
even if they were to license from nlst just dont get why any company would want to use them? with the bios changes needed? why do so many institutions own? what is their future? I just cant believe institutions are stupid.Or are they going to refocus on other products?